Effects of contractubex on the prevention of postoperative peritoneal adhesion.
BACKGROUND
There are numerus techniques and agents in use for reducing peritoneal adhesion formation. But in this research we believe this is the first research to reveal that contractubex (allium cepae, sodium heparin, and allantoin mixture) is reducing formed peritoneal adhesions. So it may be used to reduce the number of re-laparotomies/re-laparoscopies caused by peritoneal adhesions related complications.


OBJECTIVE
To evaluate the effects of contractubex (CT) in a rat model of postoperative peritoneal adhesion (PPA).


METHODS
Fifty rats were divided into four equal groups. In group 1, 1 g of CT was injected into the peritoneal cavity. In group 2, adhesions were generated. In group 3, adhesions were generated, and 1 g of CT was immediately applied into the peritoneal cavity. In group 4, adhesions were generated, and at postoperative d 7, 1 g of CT was applied into the peritoneal cavity. In group 5, adhesions were generated, and at postoperative d1, 3, 5, and 7, 1 g of CT was applied into the peritoneal cavity. The adhesions were scored both macroscopically and microscopically.


RESULTS
The mean macroscopic adhesion scores in groups 1-5 were 0 ± 0, 2.9 ± 0.21, 2.3 ± 0.54, 0.8 ± 0.63, and 2.2 ± 0.72, respectively (P < 0.0001); the mean microscopic values were 0 ± 0, 2.8 ± 0.42, 2.8 ± 0.42, 0.6 ± 0.52, and 2.3 ± 0.48, respectively (P < 0.0001). The mean macroscopic adhesion score in group 4 was lower than that in group 2 (P = 0.001). The mean macroscopic adhesion scores in groups 3 and 5 were higher than those in group 4 (P = 0.045 and P = 0.038, respectively) but did not significantly differ from those in group 2 (P = 0.171 and P = 0.124, respectively).


CONCLUSIONS
A single dose of contractubex did not prevent PPA formation but did diminish the amount of formed PPAs.
Aysan
Erhan
E
Department of General Surgery, Istanbul Teaching Hospital, Istanbul, Turkey. dr@webcerrah.com
Bektas
Hasan
H
Ersoz
Feyzullah
F
Sari
Serkan
S
Huq
Gulben
G
D000481:Allantoin / Q000627:therapeutic use*; D000818:Animals; D002921:Cicatrix / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007627:Keloid / Q000188:drug therapy; D010529:Peritoneal Cavity / Q000601:surgery; D010936:Plant Extracts / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D011693:Purpura / Q000188:drug therapy / Q000209:etiology; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000517:prevention & control*
D004338:Drug Combinations; D010936:Plant Extracts; C053099:allantoin, heparin, onion extract drug combination; D000481:Allantoin; D006493:Heparin